Latest News
ODYSSEY confirms dolutegravir-based treatment is best for children living with HIV
New extended follow-up results from the global ODYSSEY clinical trial confirm that dolutegravir-based regimens are superior to other antiretroviral treatments for children living with HIV.
'25 at 25': Optimising treatments for people with cancer
As part of our 25th anniversary celebrations, we explore our trials that aim to improve quality of life by optimising treatments for people with cancer.
Our research at the Conference on Retroviruses and Opportunistic Infections (CROI) 2024
MRC Clinical Trials Unit at UCL researchers and our collaborators will present the latest research from our HIV trials at CROI 2024.
Common antiseptic is safe for premature newborns’ skin
NeoCHG found that whole-body application of chlorhexidine is safe for hospitalised, premature newborn babies, paving the way for larger clinical trials to test how well it prevents deaths.
New prostate cancer treatments could reach men sooner
A new study shows that better prostate cancer treatments could reach men almost two years sooner than is currently possible.